Assessing Ribavirin Exposure During Pregnancy:The Ribavirin Pregnancy Registry

Gastroenterology Nursing

Volumn 31, Issue 6, 2008, Pages 413-417

  Roberts, Susan Sinclair ^a  

^a Susan Sinclair Roberts Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIBAVIRIN;

ADULT; ANIMAL; FEMALE; GESTATIONAL AGE; HEPATITIS C; HIGH RISK PREGNANCY; HUMAN; METHODOLOGY; NURSE ATTITUDE; PATIENT EDUCATION; PREGNANCY; PREGNANCY COMPLICATION; PRENATAL CARE; REGISTER; REVIEW; UNITED STATES;

ADULT; ANIMALS; FEMALE; GESTATIONAL AGE; HEPATITIS C, CHRONIC; HUMANS; NURSE'S ROLE; PATIENT EDUCATION AS TOPIC; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY, HIGH-RISK; PRENATAL CARE; REGISTRIES; RIBAVIRIN; UNITED STATES; YOUNG ADULT;

EID: 60549084792     PISSN: 1042895X     EISSN: 15389766     Source Type: Journal    
DOI: 10.1097/SGA.0b013e31818eb70d     Document Type: Article

References (17)

1. Abbott Laboratories. (2007). Humira [Prescribing information]. North Chicago, IL: Author.
2. Bianca, S., & Ettore, G. (2003). Male periconceptional ribavirin-interferon alpha-2b exposure with no adverse fetal effects. Birth Defects Research, Part A. Clinical & Molecular Teratology, 67, 77-78.
3. Centers for Disease Control and Prevention. (2001). Prevalence of HCV infection by age and gender, United States, 1988-1994. Atlanta, GA: National Center for Infectious Disease, Division of Viral Hepatitis
4. De Santis, M., Carducci, B., Cavaliere, A., De Santis, L., Lucchese, A., Straface, G., et al. (2003). Case report: Paternal exposure to ribavirin: Pregnancy and neonatal outcome. Antiviral Therapy, 8, 73-75.
5. Food and Drug Administration. (1997). Title 21-Food and Drugs (Code of Federal Regulations, Title 21, Vol. 4, Parts 200 to 299; 21CFR201.57). Washington, DC: U.S. Government Printing Office.
6. Food and Drug Administration. (2002). Guidance for industry: Establishing pregnancy exposure registries. Rockville, MD: US Department of Health and Human Services, Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research
7. Food and Drug Administration Office of Women's Health. (2007). List of pregnancy exposure registries
8. Hegenbarth, K., Maurer, U., Kroisel, P. M., Fickert, P., Trauner, M., & Stauber, R. E. (2001). No evidence for mutagenic effects of ribavirin: Report of two normal pregnancies. American Journal of Gastroenterology, 96(7), 2286-2287.
9. Kennedy, D. L., Uhl, K., & Kweder, S. L. (2004). Pregnancy exposure registries. Drug Safety, 27(4), 215-228.
10. Maddrey, W. C. (1999). Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naïve patients. Seminars in Liver Disease, 19(Suppl. 1), 67-75.
11. Mishkin, D., & Deschenes, M. (2001). Conception soon after discontinuing interferon/ribavirin therapy: A successful outcome. American Journal of Gastroenterology, 96(7), 2285-2286.
12. National Center for Health Statistics. (1999). National Vital Statistics System; Vital statistics of the United States. Public Health Service. Washington, DC: U.S. Government Printing Office
13. National Institutes of Health. (2002, June 10-12). Management of hepatitis C: Consensus development conference statement. Final statement issued September 12, 2002
14. Rezvani, M., & Koren, G. (2006). Pregnancy outcome after exposure to injectable ribavirin during embryogenesis. Reproductive Toxicology, 21(1), 113-115.
15. Roberts, S. S., Covington, D., & Doi, P. (2006). Prenatal testing prior to enrollment in pregnancy exposure registries. Pharmacoepidemiology & Drug Safety, 15(Supp. 1), S12.
16. Roche Laboratories. (2007). Copegus [Prescribing information]. Nutley, NJ: Author.
17. Schering Corporation. (2007). Rebetol [Product information]. Kenilworth, NJ: Author.